Skip to content
lifestyle.briefmobile.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Moderna, Inc.
Moderna Announces Pricing of Upsized $2.6 Billion Offering of Convertible Senior Notes
August 28, 2026
Moderna Receives U.S. FDA Approval for Updated 2026-2027 COVID-19 Vaccines
August 27, 2026
Moderna Announces Proposed Private Placement of $2.0 Billion of Convertible Senior Notes
August 27, 2026
Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA
August 5, 2026
Moderna Announces Initiation of Phase 1 Clinical Trial of mRNA-1469, Moderna’s Investigational Vaccine Against Bundibugyo Ebolavirus
August 4, 2026
Moderna Reports Second Quarter 2026 Financial Results and Provides Business Updates
July 31, 2026
Moderna Announces First Participant Dosed in Phase 1 Clinical Trial Evaluating Investigational Tumor-Targeted Cancer Antigen Therapy in Solid Tumors
July 16, 2026
Moderna to Report Second Quarter 2026 Financial Results on Friday, July 31, 2026
July 9, 2026
Moderna Appoints Michael McDonnell to Board of Directors
July 8, 2026
Moderna Science Day Highlights Expanding Potential of mRNA Platform
June 25, 2026
1
2
3
Next Page
→